In 1997, Grabowski and Mullins described why pharmacy benefit management use of pharmacoeconomics was limited. The current manuscript examines recent changes in health care payers' use of pharmacoeconomic information, payers' perceptions of that information's value for informing formulary...

Previous research indicates that in order to make pharmacoeconomic information applicable and useful for pharmaceutical benefit management (PBM) companies, several aspects need to be considered and improved. These include: timely availability of information, head-to-head comparators,...

Restrictions on the use of pharmaceuticals (such as those for low molecular weight heparins) are commonly imposed by healthcare organizations to combat rising health care costs. These restrictions can be system-based which are established by imposing specific coverage policies by insurance...

Objective: To estimate the cost per ischaemic event (death, nonfatal myocardial infarction, subsequent revascularisation procedure) avoided at 6 months in high risk patients undergoing coronary revascularisation treated with abciximab during routine medical care. Design: Retrospective, matched...